United States Anti-Obesity Drugs Market Set for Robust Growth with Rising Global Obesity Concerns 2025 | Top key players - Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb.

Market Size and Growth:

The Global Anti-Obesity Drugs Market size reached US$ 2.5 billion in 2022 and is expected to reach US$ 43.7 billion by 2030 growing with a CAGR of 45.5% during the forecast period 2024-2031.

The Anti-Obesity Drugs Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/anti-obesity-drugs-market?sz

The Anti-Obesity Drugs Market refers to the industry focused on developing, manufacturing, and commercializing pharmaceutical treatments that help manage obesity by reducing appetite, controlling calorie absorption, or enhancing metabolism. It addresses the growing global obesity burden, driven by lifestyle disorders, sedentary habits, and associated chronic diseases, creating strong demand for safe, effective, and innovative weight management therapies.

Recent Key Developments of United States (U.S):

Eli Lilly's Zepbound Success: Eli Lilly's anti-obesity drug, Zepbound (tirzepatide), has continued its market dominance, with projections indicating it will be among the world's top-selling drugs by 2030. The company announced its intention to submit a new oral obesity pill, orforglipron, for FDA approval after it met goals in a late-stage trial (August 26, 2025).

Novo Nordisk's Oral Wegovy Data: Novo Nordisk released positive clinical trial results for a higher-dose, once-daily oral version of its anti-obesity drug, Wegovy (semaglutide). The pill showed weight loss results comparable to the injectable version, with patients losing an average of 16.6% of their body weight over 64 weeks. The company anticipates a decision from the FDA on approval by the end of 2025 (September 18, 2025).

Pfizer's Re-entry into the Market: Pfizer is reportedly close to a $7.3 billion acquisition of Metsera, a biotech company developing next-generation obesity treatments. This move marks Pfizer's strategic re-entry into the anti-obesity space after discontinuing its own oral GLP-1 candidate (September 22, 2025).

High-Dose Semaglutide Clinical Trial: A clinical trial led by a UT Southwestern Medical Center researcher showed that a higher dose of semaglutide (7.2 mg weekly) led to significantly greater weight loss and metabolic benefits without an increased risk of serious side effects, suggesting a new path for patient treatment (September 15, 2025).

Viking Therapeutics' Trial Disappointment: Shares of Viking Therapeutics declined significantly after its oral anti-obesity pill failed to meet expectations in a key clinical study (August 19, 2025).

List of the Key Players in the Anti-Obesity Drugs Market:

Eli Lilly and Company
Bayer AG
Bristol-Myers Squibb
Currax Pharmaceuticals LLC
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Merck & Co. Inc.
Norgine BV
Novo Nordisk AS
Pfizer Inc.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=anti-obesity-drugs-market

Segments Covered in the Anti-Obesity Drugs Market:

By Mechanism of Action: Peripherally Acting Drugs, Centrally Acting Drugs.

By Drug Type: Prescription Drugs, OTC Drugs.

By Route of Administration: Oral, Intravenous/Subcutaneous.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/anti-obesity-drugs-market?sz

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Anti-Obesity Drugs market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Anti-Obesity Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Anti-Obesity Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Anti-Obesity Drugs Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Anti-Obesity Drugs Market in 2025?
◆ What is the projected growth rate of the Anti-Obesity Drugs Market through 2033?
◆ Who are the key players in the Anti-Obesity Drugs Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.